Meloxidyl

ประเทศ: สหภาพยุโรป

ภาษา: โปรตุเกส

แหล่งที่มา: EMA (European Medicines Agency)

ซื้อเลย

สารออกฤทธิ์:

meloxicam

มีจำหน่ายจาก:

Ceva Santé Animale

รหัส ATC:

QM01AC06

INN (ชื่อสากล):

meloxicam

กลุ่มบำบัด:

Dogs; Cats; Cattle; Pigs; Horses

พื้นที่บำบัด:

Oxicams

ข้อบ่งชี้ในการรักษา:

DogsAlleviation da inflamação e da dor, tanto aguda e crônica, desordens músculo-esqueléticas. Redução da dor pós-operatória e inflamação após cirurgia ortopedica e de tecido mole. CatsReduction de dor pós-operatória após ovariohysterectomy e pequenas cirurgias de tecidos macios. CattleFor uso em infecções respiratórias agudas, com terapêutica antibiótica adequada para reduzir os sinais clínicos em bovinos. Para uso em diarréia em combinação com terapia de reidratação oral para reduzir sinais clínicos em bezerros com mais de uma semana de idade e bovinos jovens não lactantes. Para terapia adjuvante no tratamento de mastite aguda, em combinação com terapia antibiótica. PigsFor uso não-infecciosas do aparelho locomotor transtornos para reduzir os sintomas de claudicação e inflamação. Para terapia adjuvante no tratamento de septicemia puerperal e toxemia (síndrome de mastite-metrite-agalactia) com terapia antibiótica apropriada. HorsesFor usar no alívio da inflamação e aliviar a dor, tanto aguda e crônica, desordens músculo-esqueléticas. Para o alívio da dor associada à cólica equina.

สรุปสินค้า:

Revision: 14

สถานะการอนุญาต:

Autorizado

วันที่อนุญาต:

2007-01-15

แผ่นพับข้อมูลผู้ป่วย

                                41
B. FOLHETO INFORMATIVO
42
FOLHETO INFORMATIVO
MELOXIDYL 1,5 MG/ML SUSPENSÃO ORAL PARA CÃES
10, 32 & 100 ML
1.
NOME E ENDEREÇO DO TITULAR DA AUTORIZAÇÃO DE INTRODUÇÃO NO
MERCADO E DO TITULAR DA AUTORIZAÇÃO DE FABRICO RESPONSÁVEL
PELA LIBERTAÇÃO DO LOTE, SE FOREM DIFERENTES
Titular da autorização de introdução no mercado:
Ceva Santé Animale
10 avenue de la Ballastière
33500 Libourne
França
Fabricantes responsáveis pela libertação dos lotes:
Ceva Santé Animale
Z.I. Très le Bois
22600 Loudéac
França
Vetem SpA
Lungomare Pirandello, 8
92014 Porto Empedocle (AG)
Itália
2.
NOME DO MEDICAMENTO VETERINÁRIO
Meloxidyl 1,5 mg/ml suspensão oral para cães.
Meloxicam
3.
DESCRIÇÃO DA(S) SUBSTÂNCIA(S) ACTIVA(S) E OUTROS INGREDIENTES
Cada ml contém:
- 1,5 mg de meloxicam
- 2 mg de benzoato de sódio
4.
INDICAÇÃO (INDICAÇÕES)
Alívio da inflamação e dor em doenças músculo-esqueléticas
agudas e crónicas em cães.
5.
CONTRA-INDICAÇÕES
Não administrar a animais em gestação ou lactação.
Não administrar a animais com patologia gastro-intestinal, tais como
irritação e hemorragia, funções
hepática, cardíaca ou renal diminuídas e patologias hemorrágicas,
ou quando houver evidência de
hipersensibilidade individual ao medicamento.
Não administrar a cães com menos de 6 semanas de idade.
43
6.
REACÇÕES ADVERSAS
Foram notificadas ocasionalmente reacções adversas típicas dos
AINEs, tais como perda de apetite,
vómitos, diarreia, sangue oculto nas fezes e apatia. Estas reacções
adversas ocorrem geralmente na
primeira semana de tratamento e são, na maioria dos casos,
transitórias e desaparecem logo que termina
o tratamento, mas, em casos muito raros, podem ser graves ou fatais.
A frequência dos eventos adversos é definida utilizando a seguinte
convenção:
- Muito frequente (mais de 1 em 10 animais tratados apresentando
evento(s) adverso(s))
- Frequente (mais de 1 mas menos de 10 animais em 100 animais
tratados)
- Pouco frequentes (mais de 1 mas menos de 10 animais em 1.00
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

สรุปลักษณะสินค้า

                                ANEXO I
RESUMO DAS CARACTERÍSTICAS DO MEDICAMENTO
2
1.
NOME DO MEDICAMENTO VETERINÁRIO
Meloxidyl 1,5 mg/ml suspensão oral para cães
2.
COMPOSIÇÃO QUALITATIVA E QUANTITATIVA
Composição para 1 ml
SUBSTÂNCIA(S) ACTIVA(S)
Meloxicam
1,5 mg
EXCIPIENTES:
Benzoato de sódio
2 mg
Para a lista completa de excipientes, ver secção 6.1.
3.
FORMA FARMACÊUTICA
Suspensão amarelo claro.
4.
INFORMAÇÕES CLÍNICAS
4.1
ESPÉCIE(S)-ALVO
Caninos (Cães).
4.2
INDICAÇÕES DE UTILIZAÇÃO, ESPECIFICANDO AS ESPÉCIES-ALVO
Alívio da inflamação e dor em doenças músculo-esqueléticas
agudas e crónicas.
4.3
CONTRA-INDICAÇÕES
Não administrar a animais em gestação ou lactação.
Não administrar a animais com patologias gastro-intestinais, tais
como irritação e hemorragia, funções
hepática, cardíaca ou renal diminuídas e patologias hemorrágicas,
ou quando houver evidência de
hipersensibilidade individual ao medicamento.
Não administrar a cães com menos de 6 semanas de idade.
4.4
ADVERTÊNCIAS ESPECIAIS PARA CADA ESPÉCIE-ALVO
Nenhuma.
4.5
PRECAUÇÕES ESPECIAIS DE UTILIZAÇÃO
Precauções especiais para utilização em animais
Se ocorrerem reações adversas, o tratamento deve ser interrompido e
o médico veterinário
consultado.
Evitar a administração em animais desidratados, hipovolémicos ou
hipotensos, se houver um risco
potencial de aumento da toxicidade renal.
3
Precauções especiais que devem ser tomadas pela pessoa que
administra o medicamento aos animais
As pessoas com hipersensibilidade conhecida aos anti-inflamatórios
não esteróides (AINEs) devem
evitar o contacto com o medicamento veterinário.
Em caso de ingestão acidental, dirija-se imediatamente a um médico e
mostre-lhe o folheto informativo
ou o rótulo.
4.6
REACÇÕES ADVERSAS (FREQUÊNCIA E GRAVIDADE)
Foram notificadas ocasionalmente reacções adversas típicas dos
AINEs, tais como perda de apetite,
vómitos, diarreia, sangue oculto nas fezes e apatia. Estas reacções
adversas ocorrem geralmente na
primeira semana de tratamento e
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

เอกสารเป็นภาษาอื่น

แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย บัลแกเรีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า บัลแกเรีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เดนมาร์ก 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เยอรมัน 07-02-2019
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย เอสโตเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เอสโตเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อังกฤษ 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฝรั่งเศส 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อิตาลี 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลัตเวีย 07-02-2019
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ลิทัวเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลิทัวเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฮังการี 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปแลนด์ 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โรมาเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวัก 07-02-2019
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย สโลวีเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวีเนีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฟินแลนด์ 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สวีเดน 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า นอร์เวย์ 07-02-2019
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ไอซ์แลนด์ 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ไอซ์แลนด์ 07-02-2019
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย โครเอเชีย 07-02-2019
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โครเอเชีย 07-02-2019

ค้นหาการแจ้งเตือนที่เกี่ยวข้องกับผลิตภัณฑ์นี้

ดูประวัติเอกสาร